文献速递乳腺癌

TRAK-ER研究:早期高危HR阳性HER2阴性乳腺癌的前瞻性ctDNA监测

Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study.
PubMed 文献 · Ann Oncol · 2026-10-27

TRAK-ER是一项多中心研究,对高危ER阳性HER2阴性早期乳腺癌患者在辅助内分泌治疗期间每3个月进行ctDNA监测,最长3年。912例患者开始监测,患者水平ctDNA检出率为12.0%,首次检测检出率5.0%高于后续检测的1.3%(P<0.001)。首次检测即检出ctDNA者放射学复发比例65.9%,高于后续检测检出者的26.6%(P<0.001)。

要点

  • 高危ER阳性/HER2阴性早期乳腺癌辅助内分泌治疗期间ctDNA检出率12.0%。
  • 首次检测ctDNA阳性者放射学复发比例高于后续检测阳性者。
  • ctDNA检出与淋巴结负荷正相关、与术后时间负相关。

核心结论

  • TRAK-ER结果为ER阳性早期乳腺癌ctDNA监测的实施提供依据,包括分子复发率、ctDNA检出相关因素及同期放射学复发情况。
  • 稳健识别临床复发前患者需要能检测低水平ctDNA的超灵敏方法。
  • TRAK-ER仍在进行,以评估分子复发检出后治疗的影响。

研究设计与样本

  • TRAK-ER为多中心研究,纳入高危、ER阳性、HER2阴性早期乳腺癌患者。
  • 患者在辅助内分泌治疗期间每3个月接受ctDNA监测,最长3年。
  • 高危定义为≥4枚淋巴结受累、肿瘤>5 cm,或1-3枚淋巴结受累且伴其他高危特征。
  • ctDNA检出后行分期影像,无放射学复发者随机接受palbociclib联合fulvestrant或标准内分泌治疗。
  • ctDNA分析采用肿瘤知情检测(Labcorp)。

主要发现

  • 截至2025年9月共注册1133例患者,928例完成panel设计,设计失败率16.1%(178/1106),912例开始ctDNA监测,包含5810次检测结果(每例中位7次)。
  • 首次检测ctDNA检出率为5.0%(45/897),后续检测为1.3%(66/4913)(P<0.001)。
  • 患者水平ctDNA检出率为12.0%(109/912),1.1%(10/912)的患者无既往ctDNA检出即出现临床复发。
  • ctDNA检出与淋巴结负荷正相关(P<0.001)、与分级正相关(P=0.04),与术后时间延长负相关(P=0.01)。
  • 术后5年估计累积ctDNA检出率为23.7%(95%CI 14.5-31.9%)。

临床怎么用

  • 对高危ER阳性/HER2阴性早期乳腺癌辅助内分泌治疗患者可考虑连续ctDNA监测以发现分子复发。
  • ctDNA检出后应行分期影像,无放射学复发者可进入随机治疗干预。
  • 需采用超灵敏ctDNA检测方法以在临床复发前稳健识别患者。

局限性

  • panel设计失败率为16.1%(178/1106)。
  • 部分患者无既往ctDNA检出即出现临床复发(1.1%,10/912)。
  • TRAK-ER仍在进行,分子复发检出后治疗的影响尚未获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: CtDNA detection during adjuvant endocrine therapy (ET) strongly associates with recurrence in oestrogen receptor (ER) positive early breast cancer (EBC), with potential to direct switches in adjuvant treatment. PATIENTS AND METHODS: TRAK-ER is a multicentre study for patients with high-risk, ER-positive, HER2-negative EBC, who undergo 3 monthly ctDNA surveillance for up to 3 years during adjuvant ET. High-risk included ≥4 involved lymph nodes; tumour >5 cm; 1-3 involved lymph nodes with additional high-risk features. Upon ctDNA detection, patients have staging scans and in the absence of radiological recurrence, are randomised to receive palbociclib plus fulvestrant or standard ET. ctDNA analysis was performed using a tumour informed assay (Labcorp). We report a protocol-specified analysis of ctDNA detection during surveillance, and results of contemporaneous radiological recurrence. RESULTS: 1133 patients were registered by September 2025, 928 had panels designed (design failed in 16.1% (178/1106), and 912 started ctDNA surveillance including results from 5810 tests (median 7 per patient). ctDNA detection rate was 5.0% (45/897) in the first test, and 1.3% (66/4913) in subsequent tests (P<0.001). Patient level detection rate was 12.0% (109/912), with 1.1% (10/912) of patients having a clinical recurrence without prior ctDNA detection. Detection positively associated with nodal burden (P<0.001) and grade (P=0.04) and negatively associated with increasing time from surgery (P=0.01). Estimated cumulative ctDNA detection rate at 5 years post-surgery was 23.7% (95%CI 14.5-31.9%). In patients with ctDNA detected on the first test, 65.9% (29/44) had radiological recurrence compared to 26.6% (17/64) in patients first detected on subsequent tests (P<0.001). CONCLUSION: Results from TRAK-ER inform implementation of ctDNA surveillance in ER-positive EBC, including molecular relapse rates, factors associating with ctDNA detection and contemporaneous radiological recurrence. Ultrasensitive assays detecting ctDNA at low levels, are required to robustly identify patients prior to clinical recurrence. TRAK-ER is ongoing to assess the impact of treatment after molecular relapse detection.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Cunningham N, Swift C, Cutts RJ, et al. Prospective circulating tumour DNA surveillance in patients with early high-risk hormone receptor positive, HER2-negative breast cancer in the TRAK-ER study. Ann Oncol. 2026. PMID: 42946309. doi:10.1016/j.annonc.2026.10.1292

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。